Abzena selects Sartorius Stedim Biotech to equip its US CDMO sites

Life sciences group, Abzena, has selected Sartorius Stedim Biotech to equip its integrated contract development and manufacturing organisation (CDMO) facilities in Bristol, Pennsylvania, and San Diego, California, USA.

Sartorius Stedim will provide both US facilities with end-to-end process solutions in single-use (SU) format.

John Burt, Abzena CEO, commented: “In addition to having selected Sartorius’ industry leading single-use technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process ensuring that all the data captured throughout our clients’ molecule development is transformed into process knowledge ensuring that we can rapidly develop a robust and reliable process that can be easily scaled up to ensure a smooth technology transfer.”

“We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing,” added Reinhard Vogt, Sartorius executive VP. “We look forward to working together to best serve the US and international markets.”